Abstract
Atherosclerosis is a disease characterized by accumulation of lipids and fibrous elements in the innermost layer of the arterial wall. An asymptomatic atherosclerotic plaque is characterized by a lipid core, composed of modified lipids, macrophages and T cells, which were separated from the lumen vessel by a thick fibrous cap, composed of vascular smooth muscle cell-secreted solid collagen matrix. Recently, it has been reported that expressions of TGF-β family were up regulated in human atherosclerotic plaques. In addition TGF-β family seems to plays pivotal roles for the development of atherosclerosis: TGF-β and activin A were suggested to play protective roles against the development of atherosclerotic plaques. On the other hand bone morphogenetic protein seems to play pivotal roles for the calcification of the atherosclerotic plaques. Therefore, it is debatable whether gene therapy modulating cellular signal transductions of TGF-β family is a useful tool for the inhibition of progression of atherosclerotic disease. In this review, our discussion is focused on the possibilities of gene therapies for atherosclerosis either by enhancement or suppression of cellular signaling of TGF-β family in target cells, in atherosclerotic plaques.
Keywords: gene therapy, atherosclerosis, TGF-β, activin A, BMP, Smad
Current Pharmaceutical Design
Title: Novel Ideas of Gene Therapy for Atherosclerosis: Modulation of Cellular Signal Transduction of TGF-β Family
Volume: 12 Issue: 7
Author(s): Akira Ishisaki and Hiroyuki Matsuno
Affiliation:
Keywords: gene therapy, atherosclerosis, TGF-β, activin A, BMP, Smad
Abstract: Atherosclerosis is a disease characterized by accumulation of lipids and fibrous elements in the innermost layer of the arterial wall. An asymptomatic atherosclerotic plaque is characterized by a lipid core, composed of modified lipids, macrophages and T cells, which were separated from the lumen vessel by a thick fibrous cap, composed of vascular smooth muscle cell-secreted solid collagen matrix. Recently, it has been reported that expressions of TGF-β family were up regulated in human atherosclerotic plaques. In addition TGF-β family seems to plays pivotal roles for the development of atherosclerosis: TGF-β and activin A were suggested to play protective roles against the development of atherosclerotic plaques. On the other hand bone morphogenetic protein seems to play pivotal roles for the calcification of the atherosclerotic plaques. Therefore, it is debatable whether gene therapy modulating cellular signal transductions of TGF-β family is a useful tool for the inhibition of progression of atherosclerotic disease. In this review, our discussion is focused on the possibilities of gene therapies for atherosclerosis either by enhancement or suppression of cellular signaling of TGF-β family in target cells, in atherosclerotic plaques.
Export Options
About this article
Cite this article as:
Ishisaki Akira and Matsuno Hiroyuki, Novel Ideas of Gene Therapy for Atherosclerosis: Modulation of Cellular Signal Transduction of TGF-β Family, Current Pharmaceutical Design 2006; 12 (7) . https://dx.doi.org/10.2174/138161206776056083
DOI https://dx.doi.org/10.2174/138161206776056083 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Desensitization Protocol for Rituximab-Induced Serum Sickness
Current Drug Safety Applications of FDG-PET/CT in Assessment of Vascular Infection and Inflammation
Current Molecular Imaging (Discontinued) Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases
Current Neurovascular Research Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) Animal Models of Lupus and Lupus Nephritis
Current Pharmaceutical Design Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases
Current Cancer Drug Targets Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design Cytostatic Properties of Some Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type I Receptor Antagonists
Current Pharmaceutical Design Lesson from the Pandemic: People should Always Stay Physically Active
Current Cardiology Reviews Intravenous Immunoglobulin Therapy in Dermatologic Disorders
Inflammation & Allergy - Drug Targets (Discontinued) The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy
Current Drug Targets Autoimmunity-Inducing Metals (Hg, Au and Ag) Modulate Mast Cell Signaling, Function and Survival
Current Pharmaceutical Design FDG-PET/CT in Rheumatoid Arthritis: A Review
Current Molecular Imaging (Discontinued) Reduction of Hyperproduction of Thyroid Autoantibodies in Patients without Disturbance of the Thyroid Function: New Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Neutrophil Derived Microvesicles: Emerging Role of a Key Mediator to the Immune Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Clopidogrel and Aspirin in Cardiovascular Medicine: Responders or Not -- Current Best Available Evidence
Cardiovascular & Hematological Agents in Medicinal Chemistry Adverse Cutaneous Reactions of Systemic Antihistamines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents